A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found a tolerable dosing schedule with promising activity, according to results reported by Dana-Farber Cancer Institute medical oncologist Dr. Elizabeth Lee at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

Phase I trial provides early clinical proof-of-concept supporting the combination of zedoresertib and lunresertib in certain advanced solid tumors

Zedoresertib, which targets WEE1, and lunresertib, a PKMYT1 inhibitor, are both investigational therapies that create synthetic lethality by blocking cell cycle proteins

Combination achieved notable responses in ovarian cancer at the preliminary recommended Phase II dose, with a 50% overall response rate across all patients and a 60% rate in patients with CCNE1 amplification

This combination has been granted FDA Fast Track Designation in patients with ovarian cancer harboring CCNE1 amplification, FBXW7 or PPP2R1A deleterious mutations

Nutritional epidemiology faces challenges like recall bias and confounding. Advances in AI, image recognition, and multi-omics now enable precision nutrition through personalized interventions and digital twins. The field is also shifting toward sustainable nutrition, promoting planetary health diets to protect the environment.

Wearable sensors that use microneedles to painlessly take samples at skin level could help personalize health care and enable precision drug dosing in real time, but many have been limited by weak signals and damage caused by friction in tissue.

A UCLA-led team developed a microneedle platform that operated continuously for six days in rats while improving signal quality and resistance to abrasion.

In preclinical studies, the technology not only tracked drug levels but also revealed impaired kidney and liver function based on how quickly drugs cleared from the animals’ systems — including identifying early kidney injury before conventional blood tests indicated a problem.